ADPT - Adaptive Biotechnologies Inc. Sales Growth YoY (TTM)

Adaptive Biotechnologies leads the field of immunomics, leveraging AI to decode DNA. Revenues are based on B2B deals with medical centers to develop anti-cancer agents. A neutral geopolitical backdrop complements the strategy. The 12-month year-over-year revenue growth rate confirms the development trend, where the 17.80 mark characterizes this parameter, allowing for a real-time assessment of the business expansion speed.
Adaptive Biotechnologies - analytical breakdowns and key metrics (ADPT)

Adaptive Biotechnologies generates revenue through the sale of clonoSEQ tests and strategic pharmaceutical partnerships. This indicator measures the percentage change in rolling annual revenue compared to the same period last year, neutralizing random market fluctuations. A positive vector signals scaling demand for immune sequencing, while stagnation indicates growth limits. By analyzing the rolling 12-month sales dynamics versus the prior year period, an investor determines the sustainability of the business model.